We build national genomic capability inside the country that owns it. The laboratory, the data environment, the governance and the people. We make the data earn its keep for the institution that holds it. Not a single genome leaves.
Most of the world's genomic reference data describes a minority of the world's people. The countries missing from it are told, in effect, to send their samples abroad and wait. LydiaRx makes the opposite possible. A national cohort is sequenced in-country, held on infrastructure the State controls and governed to a published standard. It is then opened to the world's researchers on the country's terms. The data never moves. The revenue is shared.
We are not a sequencing vendor, a data broker or a consultancy. We are a delivery partner. We finance the first step privately, operate the secure environment, bring the research partners and hand the country a working national asset. In every country we form a local presence (a locally registered company or office, national staff and a director resident for the pilot). We are a counterpart under the country's own law, not a visitor. Our people built the programmes that others cite.
We build genomic capability where the people are. And we stay there.
A privately financed pilot of a few hundred long-read genomes, a national pangenome built in-country, a laboratory and secure environment that stay, a trained team, a published governance standard, and a research-access framework that pays for what comes next.
A 400-genome long-read pilot and the first Pakistani pangenome, sequenced entirely in Pakistan. 12–15 Pakistani scientists trained and certified. A laboratory and secure data environment that remain a national asset. All designed to lead into a one-million-genome national programme. Read more →
A sovereign cohort and the first Maldivian pangenome, sized to an island nation, with the governed-access model that makes a small cohort valuable to research partners.
A national cohort, pangenome and in-country capability on the same model, scaled to the country and its diaspora science base.
A 500 + 500 programme: a national long-read cohort and pangenome alongside a pathogen-genomics and surveillance pillar.
A sovereign genomics programme delivered through an in-Kingdom venture: platform, laboratory operations, scientific delivery and data governance run by LydiaRx with Saudi partners.
A long-read pangenome pillar and a governed-access layer proposed alongside the national genome programme, where neither yet exists.






The individuals behind LydiaRx have built the UK's largest health-research programmes, The 100,000 Genomes Project and Our Future Health, led European RWD programmes The Get Real Institute, run one of the world's largest academic–industry sequencing partnerships and US$1 billion pharmaceutical software & data programmes, and taken two biotechnology companies to acquisition by GSK and Novartis. Meet the people →
The State. A public institution holds it under the Charter. A national-majority committee decides every use. LydiaRx takes no ownership of samples or data, during the pilot or after it.
Nothing we build depends on us staying. The laboratory, equipment and data environment are installed in the institution and offered to it; the data never left; every governance document is published; the hosting agreement provides for continuity of the platform.
Yes, by bringing their question to it. They receive governed, non-identifying results with a provenance certificate. Never a copy. The committee can refuse any request. The ledger records every one.
Start with a briefing. It commits you to nothing. A fuller statement of capability is available to governments, institutions and funders on request.